|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
7/11/2012 8:20:38 AM
The U.S. approved 33% more new cancer drugs that European nations including the United Kingdom, France, and Germany between 2000 and 2011, and approved them much faster as well, according to new research released today by the Tufts Center for the Study of Drug Development. But Americans pay for their greater access to new medicines. The cancer drugs, on average, cost 9% less in Europe. Those costs are absorbed mostly by governments and insurance companies, though U.S. health plans are more likely to make patients pay, on average, 23% or more of the price. That can cost individual cancer patients. Further complicating comparisons, and not part of the study, drug companies often work to help patients with these out-of-pocket (and bank account, and mortgage) costs.
|
|
|
|
|
|
|
|
|
|
|